JW Holdings Corporation operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares JW Holdings with three other
pharmaceutical manufacturers in Asia:
Shandong Xinhua Pharmaceutical Company Limited
sales of 3.60 billion Chinese Renmimbi [US$533.77 million]
of which 46%
Apeloa Pharmaceutical Co Ltd
(4.34 billion Chinese Renmimbi [US$643.68 million]
of which 100%
was Health Care & Pharmaceutical), and
Zhejiang NHU Co.,Ltd
based in China
(3.82 billion Chinese Renmimbi [US$566.57 million]
of which 95%
was Pharmaceutical Chemicals).
JW Holdings reported sales of 622.62 billion Korean Won (US$556.00 million)
December of 2015.
increase of 8.5%
versus 2014, when the company's sales were 573.92 billion Korean Won.
This was the third consecutive year of growth at JW Holdings.
Sales of Control Business saw an increase
that was more than double the company's growth rate: sales were up
3,375.6% in 2015, from
503.32 million Korean Won to 17.49 billion Korean Won.
JW Holdings also saw significant increases in sales in
Pharmaceuticals (up 17.7% to 571.46 billion Korean Won)
Others (up 228.0% to 29.09 billion Korean Won)